{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:06:49Z","timestamp":1793390809249,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jpurol.2019.10.009","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T11:48:46Z","timestamp":1571744926000},"page":"31.e1-31.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model\u2013based pediatric dose estimation"],"prefix":"10.1016","volume":"16","author":[{"given":"S\u00f8ren","family":"Rittig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Baka-Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-5358","authenticated-orcid":false,"given":"Johan Vande","family":"Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Kjaeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Passier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Stroosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Tannenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2019.10.009_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nrurol.2016.152","article-title":"Overactive bladder in children","volume":"13","author":"Franco","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.juro.2014.01.110","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children's Continence Society","volume":"191","author":"Austin","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/nau.22911","article-title":"Treatment of daytime urinary incontinence: a standardization document from the International Children's Continence Society","volume":"36","author":"Chang","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.10.009_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","article-title":"The neurogenic bladder: medical treatment","volume":"23","author":"Verpoorten","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11934-009-0003-1","article-title":"A randomized placebo-controlled study of the efficacy of antimuscarinics in the treatment of pediatric overactive bladder and incontinence","volume":"10","author":"Hodges","year":"2009","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.jpurol.2019.10.009_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2008.04.062","article-title":"Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial","volume":"55","author":"Marschall-Kehrel","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2016.08.061","article-title":"Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial","volume":"71","author":"Newgreen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000152322.17542.63","article-title":"Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials","volume":"173","author":"Nijman","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/nau.22446","article-title":"Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence","volume":"33","author":"van Gool","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.10.009_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.juro.2017.05.038","article-title":"Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder","volume":"198","author":"Newgreen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","article-title":"Prospective pilot study of mirabegron in pediatric patients with overactive bladder","volume":"70","author":"Blais","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib12","series-title":"Presented at the 28th ESPU congress","article-title":"Urodynamic efficacy of mirabegron in pediatric patients with spina bifida","author":"Lee","year":"2017"},{"key":"10.1016\/j.jpurol.2019.10.009_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2016.11.101","article-title":"Dual therapy for refractory overactive bladder in children: a prospective open-label study","volume":"197","author":"Morin","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib14","series-title":"Presented at ICS 2014","article-title":"Mirabegron in management of neurogenic patients with resistance to anticholinergic medicaments","author":"Skobejko","year":"2014"},{"key":"10.1016\/j.jpurol.2019.10.009_bib15","series-title":"Presented at the 28th ESPU congress","article-title":"Mirabegron in treatment of patients with neurogenic bladder resistant to anticholinergic therapy","author":"Skobejko-Wlodarska","year":"2017"},{"key":"10.1016\/j.jpurol.2019.10.009_bib16","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Clinical investigation of medicinal products in the pediatric population E11","year":"2000"},{"key":"10.1016\/j.jpurol.2019.10.009_bib17","series-title":"General clinical pharmacology considerations for pediatric studies for drugs and biological products: guidance for industry","article-title":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","author":"U.S. Department of Health and Human Services","year":"2014"},{"key":"10.1016\/j.jpurol.2019.10.009_bib18","series-title":"Recommendations of the ad hoc group for the development of implementing guidelines for Directive 2001\/20\/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use","article-title":"Ethical considerations for clinical trials on medicinal products conducted with the paediatric population","year":"2008"},{"key":"10.1016\/j.jpurol.2019.10.009_bib19","series-title":"Center for biologics evaluation and research (CBER). Guidance for industry: population pharmacokinetics","article-title":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).","author":"U.S. Department of Health and Human Services","year":"2019"},{"key":"10.1016\/j.jpurol.2019.10.009_bib20","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1208\/aapsj070248","article-title":"Population pharmacokinetic studies in pediatrics: issues in design and analysis","volume":"7","author":"Meibohm","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.jpurol.2019.10.009_bib21","first-page":"13","article-title":"Methodological issues in the design of paediatric pharmacokinetic studies","volume":"26","author":"Burckart","year":"2012","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.jpurol.2019.10.009_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00003088-200847040-00002","article-title":"Facilitation of drug evaluation in children by population methods and modelling","volume":"47","author":"Tod","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpurol.2019.10.009_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clinthera.2013.02.014","article-title":"Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults","volume":"35","author":"Lee","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpurol.2019.10.009_bib24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.clinthera.2015.02.021","article-title":"Pharmacokinetics of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects","volume":"37","author":"Iitsuka","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpurol.2019.10.009_bib25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder","volume":"50","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jpurol.2019.10.009_bib26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamapediatrics.2013.465","article-title":"Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007","volume":"167","author":"Momper","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jpurol.2019.10.009_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12040","article-title":"Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice","volume":"76","author":"Isbister","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpurol.2019.10.009_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/clpt.2012.181","article-title":"Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study","volume":"92","author":"Malik","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpurol.2019.10.009_bib29","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.2105\/AJPH.2015.302902","article-title":"Global birth prevalence of spina bifida by folic acid fortification status: a systematic review and meta-analysis","volume":"106","author":"Atta","year":"2016","journal-title":"Am J Public Health"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513119303225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513119303225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:46:28Z","timestamp":1761486388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513119303225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1477513119303225"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2019.10.009","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model\u2013based pediatric dose estimation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2019.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company.","name":"copyright","label":"Copyright"}]}}